This week's artwork was donated by Dathan, a pediatric cancer patient who received treatment at The Children's Hospital of Philadelphia . In general, these patients should be treated with single-agent chemotherapy as described for nonmetastatic disease. Patients who do not tolerate methotrexate or who become resistant to it can often be salvaged with dactinomycin. Development of intercurrent poor-risk factors, however, dictates the need for combination chemotherapy.
Careful monitoring is therefore mandatory.
Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Tumors of the placental trophoblast. High-risk metastatic trophoblastic disease. Poor-prognosis metastatic gestational trophoblastic tumor Recurrent gestational trophoblastic tumor PDQ statements exist for a number of topics. Please consult the PDQ Index .